Praxis Precision Medicines, Inc. (PRAX) Stock Price & Analysis
Praxis Precision Medicines, Inc. (PRAX) fell 1.15% to USD 250.33 as of June 10, 2026 at 01:54 UTC, according to Nexqual real-time market data.
PRAX last closed at USD 253.25; the session ranged USD 244.16–266.6 on volume of 426,392 shares. Market capitalization is $6.98B, with a 52-week range of USD 37.19–366.52 (NMS). Source: Nexqual, June 10, 2026 at 01:54 UTC.
Key Statistics (as of June 10, 2026 at 01:54 UTC)
| Price | USD 250.33 |
|---|---|
| Change | ▼ 1.15% (down) |
| Previous Close | USD 253.25 |
| Open | USD 258.01 |
| Day Range | USD 244.16 – 266.6 |
| 52-Week Range | USD 37.19 – 366.52 |
| Volume | 426,392 shares |
| Market Cap | $6.98B |
| Exchange | NMS |
Technical Analysis (PRAX)
Nexqual's technical model rates PRAX "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:54 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.63 (oversold) |
| vs SMA50 | Below (USD 322.75) |
| MACD | -19.52 (negative) |
Analyst Ratings (PRAX)
Wall Street analysts rate PRAX "Strong Buy" based on 17 analysts, with a mean price target of USD 627.59 (range USD 162–1,201), per Nexqual as of June 10, 2026 at 01:54 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 627.59 |
| High Target | USD 1,201 |
| Low Target | USD 162 |
| Buy / Hold / Sell | 15 / 1 / 1 |
Earnings (PRAX)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -3.71 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -3.2 vs est -3.68 ▲ beat |
| 2025-12-31 | USD -3.5 vs est -3.13 ▼ miss |
| 2025-09-30 | USD -3.36 vs est -3.49 ▲ beat |
| 2025-06-30 | USD -3.31 vs est -3.36 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Financials & Fundamentals (PRAX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -35.32% |
| Debt / Equity | 0.1 |
| Current Ratio | 15.88 |
| Total Cash | $786.87M |
| Total Debt | $1.44M |
| Free Cash Flow | $-176.03M |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Financial Health Score (PRAX)
Nexqual rates Praxis Precision Medicines, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:54 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $787M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$282M |
| Efficiency | Critical — ROE -35%, ROA -23.0% |
Ownership (PRAX)
| Insider Ownership | +0.32% |
|---|---|
| Institutional Ownership | +116.72% |
| Shares Outstanding | 27.88M |
| Float | 24.02M |
| Short % of Float | +13.13% |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Leadership (PRAX)
Praxis Precision Medicines, Inc. is led by Marcio Silva De'Souza (age 46), President, CEO & Director, per Nexqual as of June 10, 2026 at 01:54 UTC.
| President, CEO & Director | Marcio Silva De'Souza (age 46) |
|---|---|
| CFO & Treasurer | Timothy Edwin Kelly (age 52) |
| Co-Founder and President of Research & Development | Steven Petrou B.Sc. (Hons.) |
| Chief Operating Officer | Megan T. Sniecinski (age 44) |
Major Backers & Investors (PRAX)
Notable institutional backers of Praxis Precision Medicines, Inc. include Janus Henderson Group PLC, Orbis Allan Gray Ltd, FMR, LLC, according to Nexqual as of June 10, 2026 at 01:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 12.41% |
| Orbis Allan Gray Ltd | 8.87% |
| FMR, LLC | 7.75% |
| Perceptive Advisors Llc | 7.3% |
| Baker Bros. Advisors, LP | 6.29% |
| Deerfield Management Company, L.P | 3.46% |
| Driehaus Capital Management, LLC | 3.4% |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 3.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.52% |
| Vanguard Group | 9.74% |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
From Praxis Precision Medicines, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We submitted a New Drug Application, or NDA, for ulixacaltamide for the treatment of ET to the FDA, and have commenced commercial preparations and pre-launch activities.
- We may also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of neuroscience that may be important for the development of our business.
- Solidus™ is enabled by our proprietary, computational workflow to discover ASOs with desired drug-like properties to optimize for up/down-regulation, avoidance of toxic motifs and optimization of binding affinity and specificity.
- INTELLECTUAL PROPERTY We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties.
Partnerships
- LICENSE AGREEMENTS License Agreement with RogCon In September 2019, we and RogCon, Inc., or RogCon, entered into a Cooperation and License Agreement, or the RogCon Agreement, to collaborate to develop ASOs for the treatment of epilepsy caused by mutations of the SCN2A gene.
- RogCon had an existing collaboration arrangement with Ionis Pharmaceuticals, Inc., or Ionis, and as a result, we and Ionis negotiated a Research Collaboration, Option and License Agreement, or the Ionis Agreement, (described below) in order to complete the license agreement with RogCon.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc. | USD 10.45 | ▲ 1.36% |
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
| SRRK | Scholar Rock Holding Corporatio | USD 45.58 | ▲ 2.89% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:54 UTC. This page is informational and not investment advice.